Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Lung, Respiratory and Thoracic Cancer
Do you want to read an article? Please log in or register.